Choose Acvybra^®:

a biosimilar that delivers quality and improved access,
so you can prescribe with confidence^1,2

ACVYBRA^® matches the reference product in key characteristics:³

• Same indications³
  • Osteoporosis in postmenopausal
    women and in men at increased risk of fractures.
  • Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
  • Bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fractures.

  

• Same dosage³
• Same mode of action³